Shareholders to Vote on 8 Million Share Increase for Incentive Plan, Executive Compensation Details Disclosed
MD sits 76% above its 52-week low of $11.84.
Summary
Pediatrix Medical Group filed its definitive proxy statement, proposing to increase the share pool for its incentive compensation plan by 8 million shares, which could lead to significant future dilution. The filing also details executive compensation, including high bonuses and equity awards following strong 2025 financial performance.
Key Events · Corporate Governance and Compliance · MD
-
Proposed Incentive Plan Expansion
Shareholders will vote on increasing the share pool for the 2008 Incentive Compensation Plan by 8,000,000 shares, potentially diluting existing shareholders by approximately 9.63%.
-
Executive Compensation Details
The filing discloses 2025 executive compensation, including CEO Mark S. Ordan's total compensation of $14.14 million and bonuses paid at 180% of target, reflecting strong financial performance.
-
CEO Pay Ratio
The CEO's total compensation was approximately 91 times that of the median employee in 2025.
-
Strong 2025 Financial Performance
The company reported a significant financial turnaround in 2025, with Adjusted EBITDA reaching $275.6 million, up from $224.0 million in 2024.
Analysis · MD · Industrial Applications And Services
The definitive proxy statement outlines key proposals for the upcoming annual meeting, most notably a request to increase the share reserve for the 2008 Incentive Compensation Plan by 8,000,000 shares. If approved, this represents a potential dilution of approximately 9.63% of the current outstanding shares, which is a significant amount for shareholders. The filing also details executive compensation for 2025, showing substantial bonuses paid at 180% of target and significant equity awards, including one-time "equity transformation awards" for the CEO and Chief Investment and Strategy Officer. These compensation levels reflect the company's strong financial turnaround in 2025, with Adjusted EBITDA increasing to $275.6 million. Investors should monitor the outcome of the shareholder vote on the incentive plan due to its dilutive potential.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MD was trading at $20.79 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.84 to $24.99. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.